Biogen Company Profile (NASDAQ:BIIB)

About Biogen (NASDAQ:BIIB)

Biogen logoBiogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biopharmaceuticals
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:BIIB
  • CUSIP: 09062X10
  • Web: www.biogen.com
Capitalization:
  • Market Cap: $60.36797 billion
  • Outstanding Shares: 212,115,000
Average Prices:
  • 50 Day Moving Avg: $268.18
  • 200 Day Moving Avg: $273.81
  • 52 Week Range: $244.28 - $307.76
P/E:
  • Trailing P/E Ratio: 17.66
  • Foreward P/E Ratio: 12.44
  • P/E Growth: 2.05
Sales & Book Value:
  • Annual Revenue: $11.53 billion
  • Price / Sales: 5.19
  • Book Value: $54.12 per share
  • Price / Book: 5.21
Profitability:
  • EBIDTA: $6.04 billion
  • Net Margins: 30.17%
  • Return on Equity: 38.17%
  • Return on Assets: 20.51%
Debt:
  • Debt-to-Equity Ratio: 0.52%
  • Current Ratio: 2.29%
  • Quick Ratio: 1.98%
Misc:
  • Average Volume: 1.55 million shs.
  • Beta: 0.78
  • Short Ratio: 1.68
 

Frequently Asked Questions for Biogen (NASDAQ:BIIB)

What is Biogen's stock symbol?

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

How were Biogen's earnings last quarter?

Biogen Inc. (NASDAQ:BIIB) posted its quarterly earnings data on Tuesday, April, 25th. The company reported $5.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.97 by $0.23. The business earned $2.81 billion during the quarter, compared to the consensus estimate of $2.73 billion. Biogen had a net margin of 30.17% and a return on equity of 38.17%. The firm's quarterly revenue was up 3.1% compared to the same quarter last year. During the same quarter last year, the company posted $4.79 earnings per share. View Biogen's Earnings History.

When will Biogen make its next earnings announcement?

Biogen is scheduled to release their next quarterly earnings announcement on Tuesday, July, 25th 2017. View Earnings Estimates for Biogen.

Where is Biogen's stock going? Where will Biogen's stock price be in 2017?

24 equities research analysts have issued 12 month price targets for Biogen's stock. Their forecasts range from $271.00 to $442.00. On average, they expect Biogen's share price to reach $327.76 in the next twelve months. View Analyst Ratings for Biogen.

What are analysts saying about Biogen stock?

Here are some recent quotes from research analysts about Biogen stock:

  • 1. Cantor Fitzgerald analysts commented, "A German patient treated for three years with Tysabri and then with a single dose of Ocrevus developed PML." (5/25/2017)
  • 2. Cowen and Company analysts commented, "Biogen reported Q1 revenues of $2.81B (+3% Y/Y, vs. consensus of $2.74B) and non-." (4/25/2017)
  • 3. Mizuho analysts commented, "We just started our Spinraza webinar … here’s a link to the slides pdf Rating Neutral Previous Rating No Change Price (4/17) $274.05 Price Target $290.00 Previous Price Target No Change LINK to slides for our Spinraza webinar (for folks who prefer a pdf copy): CLICK HERE Link to join webinar (just started): CLICK HERE We intend to blast a replay of the webinar after we finish. PLEASE REFER TO PAGE 3 OF THIS REPORT FOR IMPORTANT DISCLOSURE AND ANALYST CERTIFICATION INFORMATION. Mizuho Securities USA LLC does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision." (4/18/2017)
  • 4. Instinet analysts commented, "We are initiating on BIIB with a Buy rating and $345 target price. We recommend owning BIIB shares over the next 12 months given limited 2017 downside to revenue forecasts and potential Spinraza launch upside. We estimate that a successful Spinraza launch will drive above-consensus revenues of $11.6bn in 2017 and $12.2bn in 2018, despite flat MS-franchise growth that may be impacted by emerging competition (Ocrevus). We anticipate this return to growth will drive modest revenue multiple expansion and strong GAAP EPS growth - to $19.41 in 2017 and $21.56 in 2018, yielding upside to our $345 target price." (3/1/2017)
  • 5. Jefferies Group LLC analysts commented, "This morning BIIB announced a settlement with FWP around Tecfidera IP. While we believe Street expectations were generally balanced going into the 3/17 decision (and we had assumed 50/50 prob. BIIB would be successful), commercial and some IPR risk remains, and recent focus has been more on Spinraza launch and Alzheimer’s, the terms look reasonable to us and help reduce an overhang." (1/18/2017)

Who are some of Biogen's key competitors?

Who are Biogen's key executives?

Biogen's management team includes the folowing people:

  • Stelios B. Papadopoulos Ph.D., Independent Chairman of the Board
  • Michel Vounatsos, Chief Executive Officer, Director
  • Gregory F. Covino, Interim Principal Financial Officer, Chief Accounting Officer, Vice President - Finance
  • Kenneth A. Di Pietro, Executive Vice President - Human Resources
  • Susan H. Alexander Esq., Executive Vice President, Chief Legal Officer and Corporate Secretary
  • Michael D. Ehlers M.D., Ph.D., Executive Vice President, Head - Research and Development
  • Adriana Karaboutis, Executive Vice President - Technology , Business Solutions and Corporate Affairs
  • Jean-Paul Kress M.D., Executive Vice President, President - International and Head of Global Therapeutic Operations
  • Paul McKenzie Ph.D., Executive Vice President - Pharmaceutical Operations & Technology
  • Alfred W. Sandrock Jr., M.D., Ph.D., Executive Vice President - Neurology Discovery and Development and Chief Medical Officer

Who owns Biogen stock?

Biogen's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Swedbank (0.27%), Bank of Montreal Can (0.21%), Rockefeller Financial Services Inc. (0.12%), Waverton Investment Management Ltd (0.10%), Chevy Chase Trust Holdings Inc. (0.09%) and National Pension Service (0.08%). Company insiders that own Biogen stock include Adam Koppel, Adriana Karaboutis, Alexander J Denner, Alfred Sandrock, Brian S Posner, Caroline Dorsa, George A Scangos, Michel Vounatsos, Paul J Clancy, Robert W Pangia and Stelios Papadopoulos. View Institutional Ownership Trends for Biogen.

Who sold Biogen stock? Who is selling Biogen stock?

Biogen's stock was sold by a variety of institutional investors in the last quarter, including Swedbank, DnB Asset Management AS, NN Investment Partners Holdings N.V., Nisa Investment Advisors LLC, Bedrijfstakpensioenfonds Voor DE Media PNO, Exxonmobil Investment Management Inc. TX, Meeder Asset Management Inc. and Creative Planning. Company insiders that have sold Biogen stock in the last year include Adriana Karaboutis, Alfred Sandrock, Brian S Posner, Caroline Dorsa, George A Scangos, Paul J Clancy and Robert W Pangia. View Insider Buying and Selling for Biogen.

Who bought Biogen stock? Who is buying Biogen stock?

Biogen's stock was acquired by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Exane Asset Management, First Quadrant L P CA, Rockefeller Financial Services Inc., Mn Services Vermogensbeheer B.V., Factory Mutual Insurance Co., Gateway Investment Advisers LLC and Waverton Investment Management Ltd. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner, Michel Vounatsos and Stelios Papadopoulos. View Insider Buying and Selling for Biogen.

How do I buy Biogen stock?

Shares of Biogen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biogen's stock price today?

One share of Biogen stock can currently be purchased for approximately $281.95.


MarketBeat Community Rating for Biogen (NASDAQ BIIB)
Community Ranking:  3.2 out of 5 (  )
Outperform Votes:  1,081 (Vote Outperform)
Underperform Votes:  620 (Vote Underperform)
Total Votes:  1,701
MarketBeat's community ratings are surveys of what our community members think about Biogen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Biogen (NASDAQ:BIIB) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 11 Hold Ratings, 12 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.58)
Consensus Price Target: $327.76 (16.25% upside)

Analysts' Ratings History for Biogen (NASDAQ:BIIB)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/18/2017BMO Capital MarketsReiterated RatingHold$318.00LowView Rating Details
7/14/2017Credit Suisse GroupSet Price TargetHold$300.00LowView Rating Details
7/11/2017Jefferies Group LLCReiterated RatingHold -> Hold$310.00LowView Rating Details
7/10/2017Morgan StanleyReiterated RatingEqual WeightLowView Rating Details
7/3/2017Cowen and CompanyReiterated RatingOutperform$271.00MediumView Rating Details
6/26/2017William BlairReiterated RatingOutperformHighView Rating Details
6/23/2017Deutsche Bank AGInitiated CoverageBuy$315.00LowView Rating Details
6/22/2017Leerink SwannReiterated RatingMarket PerformLowView Rating Details
5/31/2017MizuhoLower Price TargetNeutral$290.00 -> $274.00LowView Rating Details
5/25/2017Sanford C. BernsteinReiterated RatingOutperformLowView Rating Details
5/25/2017Cantor FitzgeraldReiterated RatingHold$277.00LowView Rating Details
5/15/2017Piper Jaffray CompaniesSet Price TargetBuy$332.00 -> $442.00LowView Rating Details
4/26/2017Stifel NicolausBoost Price TargetHold$265.00 -> $280.00MediumView Rating Details
4/23/2017Barclays PLCReiterated RatingOverweight$380.00 -> $360.00MediumView Rating Details
4/18/2017Robert W. BairdReiterated RatingNeutral$290.00LowView Rating Details
4/4/2017Citigroup Inc.Boost Price TargetBuy$305.00 -> $315.00LowView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$223.03 -> $345.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageNeutralN/AView Rating Details
2/2/2017Royal Bank Of CanadaReiterated RatingBuyN/AView Rating Details
1/30/2017HC WainwrightReiterated RatingBuy$360.00N/AView Rating Details
1/18/2017J P Morgan Chase & CoReiterated RatingBuyN/AView Rating Details
12/29/2016Raymond James Financial, Inc.Boost Price TargetStrong-Buy$375.00 -> $386.00N/AView Rating Details
9/22/2016Bank of America CorporationReiterated RatingBuy$374.00N/AView Rating Details
8/2/2016Standpoint ResearchDowngradeBuy -> HoldN/AView Rating Details
6/8/2016Wells Fargo & CompanyReiterated RatingBuyN/AView Rating Details
4/23/2016Goldman Sachs Group, Inc. (The)Reiterated RatingHoldN/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageOverweight$344.00N/AView Rating Details
9/23/2015Oppenheimer Holdings, Inc.Reiterated RatingSector PerformN/AView Rating Details
7/27/2015ArgusLower Price TargetBuy$450.00 -> $360.00N/AView Rating Details
(Data available from 7/20/2015 forward)

Earnings

Earnings History for Biogen (NASDAQ:BIIB)
Earnings by Quarter for Biogen (NASDAQ:BIIB)
Earnings History by Quarter for Biogen (NASDAQ BIIB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/25/2017$4.50N/AView Earnings Details
4/25/2017Q1 2017$4.97$5.20$2.73 billion$2.81 billionViewN/AView Earnings Details
1/26/2017Q416$4.96$5.04$2.94 billion$2.87 billionViewN/AView Earnings Details
10/26/2016Q316$4.97$5.19$2.91 billion$2.96 billionViewListenView Earnings Details
7/21/2016Q216$4.69$5.21$2.79 billion$2.89 billionViewListenView Earnings Details
4/21/2016Q116$4.47$4.79$2.75 billion$2.73 billionViewListenView Earnings Details
1/27/2016Q415$4.08$4.50$2.70 billion$2.84 billionViewListenView Earnings Details
10/21/2015Q315$3.80$4.48$2.65 billion$2.39 billionViewListenView Earnings Details
7/24/2015Q215$4.10$4.22$2.71 billion$2.59 billionViewListenView Earnings Details
4/24/2015Q115$3.91$3.82$2.66 billion$2.56 billionViewListenView Earnings Details
1/29/2015Q414$3.74$4.09$2.64 billion$2.60 billionViewListenView Earnings Details
10/22/2014Q3$3.22$3.80$2.48 billion$2.50 billionViewListenView Earnings Details
7/23/2014Q214$2.80$3.49$2.14 billion$2.42 billionViewListenView Earnings Details
4/23/2014Q114$2.56$2.47$2.00 billion$2.10 billionViewListenView Earnings Details
1/29/2014Q413$2.27$2.34$1.93 billion$2.00 billionViewListenView Earnings Details
10/28/2013Q313$2.10$2.35$1.78 billion$1.83 billionViewListenView Earnings Details
7/25/2013Q2 2013$1.93$2.30$1.62 billion$1.70 billionViewListenView Earnings Details
4/25/2013Q1 2013$1.63$1.97$1.41 billion$1.40 billionViewListenView Earnings Details
1/28/2013Q4 2012$1.46$1.40$1.38 billion$1.40 billionViewListenView Earnings Details
10/25/2012$1.60$1.91ViewN/AView Earnings Details
7/24/2012$1.56$1.82ViewN/AView Earnings Details
5/1/2012$1.49$1.40ViewN/AView Earnings Details
1/31/2012$1.49$1.51ViewN/AView Earnings Details
10/28/2011$1.52$1.61ViewN/AView Earnings Details
7/26/2011$1.36$1.36ViewN/AView Earnings Details
4/21/2011$1.41$1.43ViewN/AView Earnings Details
2/1/2011$1.23$1.42ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Biogen (NASDAQ:BIIB)
2017 EPS Consensus Estimate: $19.28
2018 EPS Consensus Estimate: $22.52
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$4.47$5.03$4.75
Q2 20173$3.92$4.11$4.04
Q3 20173$4.91$5.46$5.22
Q4 20174$4.94$5.41$5.26
Q1 20181$5.30$5.30$5.30
Q2 20181$5.60$5.60$5.60
Q3 20181$5.78$5.78$5.78
Q4 20181$5.84$5.84$5.84
Q1 20191$5.91$5.91$5.91
Q2 20191$6.11$6.11$6.11
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Biogen (NASDAQ:BIIB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Biogen (NASDAQ:BIIB)
Insider Ownership Percentage: 0.32%
Institutional Ownership Percentage: 87.47%
Insider Trades by Quarter for Biogen (NASDAQ:BIIB)
Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)
Insider Trades by Quarter for Biogen (NASDAQ:BIIB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/9/2017Brian S PosnerDirectorSell1,084$256.31$277,840.04View SEC Filing  
5/1/2017Michel VounatsosCEOBuy1,402$271.35$380,432.70View SEC Filing  
4/27/2017Alexander J. DennerDirectorBuy73,858$278.50$20,569,453.00View SEC Filing  
4/25/2017Paul J ClancyVPSell9,892$290.00$2,868,680.00View SEC Filing  
4/3/2017Alfred SandrockCMOSell1,981$274.08$542,952.48View SEC Filing  
3/13/2017Paul J ClancyVPSell9,891$291.55$2,883,721.05View SEC Filing  
2/27/2017Michel VounatsosCEOBuy1,333$285.39$380,424.87View SEC Filing  
1/9/2017Robert W PangiaDirectorSell5,450$295.39$1,609,875.50View SEC Filing  
10/4/2016Adriana KaraboutisEVPSell262$311.94$81,728.28View SEC Filing  
10/3/2016Adriana KaraboutisEVPSell380$313.00$118,940.00View SEC Filing  
9/22/2016Caroline DorsaDirectorSell27,570$314.00$8,656,980.00View SEC Filing  
7/21/2016George A ScangosCEOSell157$280.00$43,960.00View SEC Filing  
6/6/2016Adam KoppelEVPSell555$290.00$160,950.00View SEC Filing  
6/3/2016George A ScangosCEOSell842$290.00$244,180.00View SEC Filing  
6/1/2016George A ScangosCEOSell3,855$289.74$1,116,947.70View SEC Filing  
5/25/2016George A ScangosCEOSell157$280.00$43,960.00View SEC Filing  
5/2/2016George A ScangosCEOSell487$274.74$133,798.38View SEC Filing  
4/6/2016Adam KoppelEVPSell102$275.00$28,050.00View SEC Filing  
4/6/2016George A ScangosCEOSell157$280.00$43,960.00View SEC Filing  
4/1/2016George A ScangosCEOSell487$258.83$126,050.21View SEC Filing  
3/1/2016George A ScangosCEOSell487$261.37$127,287.19View SEC Filing  
2/25/2016Adriana KaraboutisEVPSell84$261.90$21,999.60View SEC Filing  
2/25/2016Alfred SandrockCMOSell183$261.90$47,927.70View SEC Filing  
2/17/2016Alfred SandrockChief Medical OfficerSell722$256.16$184,947.52View SEC Filing  
2/17/2016George A ScangosCEOSell487$256.16$124,749.92View SEC Filing  
2/9/2016Alfred SandrockChief Medical OfficerSell852$246.54$210,052.08View SEC Filing  
12/4/2015Alfred SandrockCMOSell441$277.00$122,157.00View SEC Filing  
10/23/2015Alexander J DennerDirectorBuy310,000$277.47$86,015,700.00View SEC Filing  
7/27/2015Stelios PapadopoulosDirectorBuy10,000$304.88$3,048,800.00View SEC Filing  
6/19/2015Douglas E WilliamsEVPSell3,841$410.00$1,574,810.00View SEC Filing  
6/1/2015George A ScangosCEOSell1,362$398.87$543,260.94View SEC Filing  
4/1/2015George A ScangosCEOSell1,362$423.20$576,398.40View SEC Filing  
3/25/2015John CoxEVPSell12,010$449.06$5,393,210.60View SEC Filing  
3/20/2015Eric K RowinskyDirectorSell11,667$475.00$5,541,825.00View SEC Filing  
3/19/2015Eric K RowinskyDirectorSell2,333$436.14$1,017,514.62View SEC Filing  
3/17/2015Eric K RowinskyDirectorSell4,667$425.45$1,985,575.15View SEC Filing  
3/10/2015Robert W PangiaDirectorSell3,625$413.40$1,498,575.00View SEC Filing  
3/2/2015Alfred SandrockSVPSell3,174$409.49$1,299,721.26View SEC Filing  
2/17/2015Steven H HoltzmanEVPSell2,128$389.11$828,026.08View SEC Filing  
2/10/2015Alfred SandrockSVPSell1,143$398.11$455,039.73View SEC Filing  
2/2/2015Kenneth DipietroEVPSell1,656$389.03$644,233.68View SEC Filing  
12/15/2014Spyridon Artavanis-TsakonasSVPSell1,981$346.50$686,416.50View SEC Filing  
12/2/2014Steven H HoltzmanEVPSell1,749$335.65$587,051.85View SEC Filing  
11/11/2014Steven H HoltzmanEVPSell1,750$330.00$577,500.00View SEC Filing  
11/3/2014George A ScangosCEOSell1,128$320.78$361,839.84View SEC Filing  
10/1/2014George A ScangosCEOSell1,127$330.97$373,003.19View SEC Filing  
10/1/2014Steven H HoltzmanEVPSell1,750$330.97$579,197.50View SEC Filing  
8/1/2014George A ScangosCEOSell1,128$332.93$375,545.04View SEC Filing  
7/16/2014George A ScangosCEOSell12,316$312.37$3,847,148.92View SEC Filing  
5/19/2014Steven HoltzmanEVPSell1,221$289.15$353,052.15View SEC Filing  
5/1/2014George ScangosCEOSell2,123$285.56$606,243.88View SEC Filing  
4/17/2014Steven HoltzmanEVPSell1,221$291.00$355,311.00View SEC Filing  
4/1/2014George ScangosCEOSell2,123$308.42$654,775.66View SEC Filing  
4/1/2014Robert PangiaDirectorSell6,250$308.42$1,927,625.00View SEC Filing  
3/31/2014Brian PosnerDirectorSell3,000$296.76$890,280.00View SEC Filing  
3/20/2014Caroline DorsaDirectorSell10,000$348.88$3,488,800.00View SEC Filing  
3/19/2014Douglas WilliamsEVPSell3,505$352.29$1,234,776.45View SEC Filing  
3/17/2014Steven HoltzmanEVPSell1,221$334.83$408,827.43View SEC Filing  
3/11/2014Stuart KingsleyEVPSell8,428$336.83$2,838,803.24View SEC Filing  
3/3/2014George ScangosCEOSell2,942$335.79$987,894.18View SEC Filing  
2/26/2014Alfred SandrockSVPSell1,048$342.17$358,594.16View SEC Filing  
2/18/2014Steven HoltzmanEVPSell1,222$327.90$400,693.80View SEC Filing  
2/13/2014Kenneth DipietroEVPSell1,290$316.81$408,684.90View SEC Filing  
2/11/2014Alfred SandrockSVPSell2,085$314.31$655,336.35View SEC Filing  
2/11/2014George ScangosCEOSell2,456$314.31$771,945.36View SEC Filing  
2/4/2014Kenneth DipietroEVPSell1,655$299.01$494,861.55View SEC Filing  
1/21/2014Eric RowinskyDirectorSell2,020$310.09$626,381.80View SEC Filing  
1/15/2014Lynn SchenkDirectorSell1,000$297.48$297,480.00View SEC Filing  
1/8/2014William YoungDirectorSell15,000$285.11$4,276,650.00View SEC Filing  
1/6/2014Robert PangiaDirectorSell6,250$278.03$1,737,687.50View SEC Filing  
12/2/2013Lynn SchenkDirectorSell1,000$291.71$291,710.00View SEC Filing  
11/22/2013Raymond PawlickiSVPSell4,000$288.00$1,152,000.00View SEC Filing  
11/1/2013George A ScangosCEOSell2,239$245.57$549,831.23View SEC Filing  
11/1/2013Lynn SchenkDirectorSell1,000$245.00$245,000.00View SEC Filing  
10/22/2013Alfred SandrockSVPSell15,030$250.11$3,759,153.30View SEC Filing  
9/18/2013Paul ClancyCFOSell26,785$245.00$6,562,325.00View SEC Filing  
9/17/2013Steven HoltzmanEVPSell3,501$238.98$836,668.98View SEC Filing  
9/16/2013Paul ClancyCFOSell99,030$238.27$23,595,878.10View SEC Filing  
9/16/2013Raymond PawlickiSVPSell4,000$238.03$952,120.00View SEC Filing  
9/3/2013George ScangosCEOSell2,239$214.40$480,041.60View SEC Filing  
8/26/2013Douglas WilliamsEVPSell4,368$211.35$923,176.80View SEC Filing  
8/1/2013George A ScangosCEOSell2,239$218.82$489,937.98View SEC Filing  
7/16/2013George A ScangosCEOSell2,239$223.94$501,401.66View SEC Filing  
6/14/2013Alexander J DennerDirectorSell2,900$212.00$614,800.00View SEC Filing  
6/11/2013Brian S PosnerDirectorSell2,020$219.62$443,632.40View SEC Filing  
6/10/2013Lynn SchenkDirectorSell2,000$225.82$451,640.00View SEC Filing  
6/3/2013George A ScangosCEOSell1,598$234.16$374,187.68View SEC Filing  
6/3/2013Stephen A SherwinDirectorSell12,825$233.26$2,991,559.50View SEC Filing  
5/28/2013Robert W PangiaDirectorSell5,900$237.23$1,399,657.00View SEC Filing  
12/27/2012Alexander J DennerDirectorSell7,980$148.62$1,185,987.60View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Biogen (NASDAQ:BIIB)
Latest Headlines for Biogen (NASDAQ:BIIB)
Source:
DateHeadline
americanbankingnews.com logoQ2 2017 Earnings Forecast for Biogen Inc. Issued By Leerink Swann (NASDAQ:BIIB)
www.americanbankingnews.com - July 19 at 11:40 AM
americanbankingnews.com logoLeerink Swann Analysts Raise Earnings Estimates for Biogen Inc. (BIIB)
www.americanbankingnews.com - July 18 at 2:44 PM
americanbankingnews.com logoBiogen Inc. (BIIB) to Release Earnings on Tuesday
www.americanbankingnews.com - July 18 at 8:27 AM
americanbankingnews.com logoBiogen Inc. (BIIB) Given "Hold" Rating at Credit Suisse Group
www.americanbankingnews.com - July 15 at 1:40 PM
americanbankingnews.com logoBiogen Inc. (BIIB) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - July 14 at 3:19 PM
fool.com logoHow Biogen Inc. Makes Most of Its Money
www.fool.com - July 13 at 4:46 PM
americanbankingnews.com logoBiogen Inc. Forecasted to Post Q2 2017 Earnings of $3.92 Per Share (NASDAQ:BIIB)
www.americanbankingnews.com - July 13 at 9:16 AM
nasdaq.com logoThe Math Shows BBH Can Go To $140 - Nasdaq
www.nasdaq.com - July 12 at 5:05 PM
americanbankingnews.com logo Analysts Anticipate Biogen Inc. (NASDAQ:BIIB) Will Announce Quarterly Sales of $2.81 Billion
www.americanbankingnews.com - July 12 at 9:34 AM
americanbankingnews.com logoBiogen's (NASDAQ:BIIB) "Equal Weight" Rating Reaffirmed at Morgan Stanley
www.americanbankingnews.com - July 10 at 9:40 PM
americanbankingnews.com logoBiogen Inc. (NASDAQ:BIIB) Expected to Post Earnings of $4.42 Per Share
www.americanbankingnews.com - July 10 at 8:10 PM
americanbankingnews.com logoBiogen Inc. (NASDAQ:BIIB) Rating Lowered to Buy at Vetr Inc.
www.americanbankingnews.com - July 9 at 4:10 PM
seekingalpha.com logoEMA restricts Biogen MS drug while investigating liver safety ... - Seeking Alpha
seekingalpha.com - July 8 at 4:12 PM
americanbankingnews.com logoEquities Analysts Issue Forecasts for Biogen Inc.'s Q1 2018 Earnings (NASDAQ:BIIB)
www.americanbankingnews.com - July 7 at 11:58 AM
americanbankingnews.com logoBiogen Inc. (NASDAQ:BIIB) Upgraded at Vetr Inc.
www.americanbankingnews.com - July 7 at 12:38 AM
bizjournals.com logoBiogen aims to block Tecfidera generics with flurry of lawsuits - Boston Business Journal
www.bizjournals.com - July 5 at 1:26 AM
americanbankingnews.com logoBiogen Inc. (NASDAQ:BIIB) Given Outperform Rating at Cowen and Company
www.americanbankingnews.com - July 3 at 8:56 PM
finance.yahoo.com logoLike Biogen, this Fidelity-backed startup is targeting a deadly infant disease
finance.yahoo.com - June 28 at 3:17 PM
finance.yahoo.com logoBiogen Appoints Catherine Steele Senior Vice President of Corporate Affairs
finance.yahoo.com - June 28 at 3:17 PM
finance.yahoo.com logoWhat’s in Biogen’s Clinical Pipeline?
finance.yahoo.com - June 28 at 3:17 PM
americanbankingnews.com logoWilliam Blair Comments on Biogen Inc.'s Q2 2017 Earnings (BIIB)
www.americanbankingnews.com - June 28 at 7:36 AM
americanbankingnews.com logoBiogen Inc. (BIIB) Raised to "Strong-Buy" at Vetr Inc.
www.americanbankingnews.com - June 28 at 12:38 AM
americanbankingnews.com logoWilliam Blair Comments on Biogen Inc.'s FY2020 Earnings (BIIB)
www.americanbankingnews.com - June 27 at 3:26 PM
americanbankingnews.com logoBiogen Inc. (BIIB) Forecasted to Post FY2018 Earnings of $22.14 Per Share
www.americanbankingnews.com - June 26 at 11:04 AM
americanbankingnews.com logoBiogen Inc. (BIIB) Lifted to Buy at ValuEngine
www.americanbankingnews.com - June 25 at 12:10 AM
americanbankingnews.com logoBiogen Inc. (BIIB) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - June 24 at 10:58 PM
americanbankingnews.com logoBiogen Inc. (BIIB) Now Covered by Analysts at Deutsche Bank AG
www.americanbankingnews.com - June 23 at 12:12 PM
americanbankingnews.com logoBiogen's (BIIB) Market Perform Rating Reaffirmed at Leerink Swann
www.americanbankingnews.com - June 22 at 11:04 PM
finance.yahoo.com logoBiogen, Inc. – Value Analysis (NASDAQ:BIIB) : June 22, 2017
finance.yahoo.com - June 22 at 9:05 PM
americanbankingnews.com logoBiogen Inc. (BIIB) Stock Rating Lowered by Vetr Inc.
www.americanbankingnews.com - June 22 at 12:34 AM
marketwatch.com logoBiogen's stock jumps after UBS boosts rating, price target - MarketWatch
www.marketwatch.com - June 20 at 2:09 AM
finance.yahoo.com logoThe Near-Term Setup For Biogen Has Positive Risk/Reward Written All Over It
finance.yahoo.com - June 19 at 9:06 PM
finance.yahoo.com logoUS STOCKS-Wall St hits record highs on strong technology, health stocks
finance.yahoo.com - June 19 at 9:06 PM
nasdaq.com logoMonday Sector Leaders: Healthcare, Technology & Communications
www.nasdaq.com - June 19 at 4:05 PM
reuters.com logoWall St. at record highs on technology, health stocks strength
www.reuters.com - June 19 at 4:05 PM
americanbankingnews.com logoBiogen Inc. (BIIB) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - June 19 at 2:28 PM
americanbankingnews.com logoBiogen Inc. (BIIB) Expected to Announce Quarterly Sales of $2.81 Billion
www.americanbankingnews.com - June 16 at 1:54 PM
finance.yahoo.com logo​Accenture, 1QBit partner for drug discovery through quantum computing
finance.yahoo.com - June 15 at 10:45 PM
investorplace.com logoDon't Be Scared of Biogen Inc (BIIB) Stock - Investorplace.com
investorplace.com - June 15 at 5:44 PM
investorplace.com logoDon’t Be Scared of Biogen Inc (BIIB) Stock
investorplace.com - June 15 at 9:55 AM
thestreet.com logoCFO Departure Signals Biogen Isn't About To Be Sold - TheStreet.com
www.thestreet.com - June 14 at 9:12 PM
americanbankingnews.com logoZacks: Analysts Anticipate Biogen Inc (BIIB) Will Post Earnings of $4.40 Per Share
www.americanbankingnews.com - June 14 at 6:20 PM
americanbankingnews.com logoBiogen Inc (BIIB) Earns "Equal Weight" Rating from Morgan Stanley
www.americanbankingnews.com - June 14 at 5:20 PM
marketwatch.com logoAlexion hires Biogen executive to serve as its CFO - MarketWatch
www.marketwatch.com - June 14 at 10:42 AM
247wallst.com logoAlexion Pharmaceuticals Adds New CFO From Biogen - 24/7 Wall St.
247wallst.com - June 14 at 10:42 AM
finance.yahoo.com logoCelgene's Next Blockbuster: What You Need to Know
finance.yahoo.com - June 13 at 1:04 PM
americanbankingnews.com logoInsider Selling: Biogen Inc. (BIIB) Director Sells 1,084 Shares of Stock
www.americanbankingnews.com - June 12 at 7:34 PM
americanbankingnews.com logoValuEngine Downgrades Biogen Inc. (BIIB) to Hold
www.americanbankingnews.com - June 12 at 12:40 AM
investorplace.com logoBiogen Inc (BIIB) Stock Can Help You Earn Income From Thin Air
investorplace.com - June 5 at 10:22 AM
finance.yahoo.com logoBiogen/Ionis Spinraza Granted Marketing Authorization in EU
finance.yahoo.com - June 2 at 5:15 PM

Social

Chart

Biogen (BIIB) Chart for Thursday, July, 20, 2017

This page was last updated on 7/20/2017 by MarketBeat.com Staff